Research programme: beta-lactamase inhibitors - Roche

Drug Profile

Research programme: beta-lactamase inhibitors - Roche

Alternative Names: FPI 1465

Latest Information Update: 11 Nov 2015

Price : $50

At a glance

  • Originator NAEJA Pharmaceutical
  • Class Amides; Heterocyclic bicyclo compounds
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 12 Sep 2013 Antimicrobial and adverse events data from preclinical trials in Bacterial infections presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2013)
  • 27 Aug 2013 Preclinical trials in Bacterial infections (adjunctive treatment) in Canada (Parenteral)
  • 30 Mar 2012 Fedora Pharmceuticals acquires exclusive worldwide rights to a family of beta-lactamase inhibitors from NAEJA Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top